[Heptaminol adenosine phosphate and the premenstrual syndrome].
The efficacy of the adenosine phosphate of heptaminol on the functional symptomatology of the premenstrual syndrome has been assessed in the framework of an "open" controlled trial against a reference product. 45 women received adenosine phosphate of heptaminol (6 gelatine capsules/day) or the reference product during 2 cycles. The statistical analysis of the results by symptom demonstrates the markedly superior activity of the adenosine phosphate of heptaminol on pelvic pains (p less than 0.02), and on the pains and heaviness of the lower limbs (p less than 0.05). The superiority of adenosine phosphate of heptaminol was similarly demonstrated in the global evaluation of results. The tolerance must be regarded as excellent.
D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D004145:Diosmin / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011293:Premenstrual Syndrome / Q000188:drug therapy*; D013566:Sympathomimetics / Q000627:therapeutic use*; D013577:Syndrome
D005419:Flavonoids; D013566:Sympathomimetics; C027557:heptaminol adenylate; D000249:Adenosine Monophosphate; D004145:Diosmin
Adénosine phosphate d'heptaminol et syndrome prémenstruel.